DUSA Pharmaceuticals (DUSA) Announces Marketing Approval in Korea
More News related to DUSA
- DUSA Pharma (DUSA) Encouraged By SCC Study to Explore Benefits of Levulan PDT
- Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
- DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
- DUSA Pharma (DUSA) Posts Q3 Loss of 2c, Beats by 2c
- DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) said the Korea Food and Drug Administration has approved Levulan Kerastick for Photodynamic Therapy for the treatment of actinic keratoses through its marketing partner Daewoong Pharmaceutical Co., Ltd and its affiliate, DNC Daewoong Derma & Plastic Surgery Network Company.
Having received approval, market launch is expected in the first quarter of 2008.
Related Categories
FDAStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
